Rohr A S, Marshall N A, Saxon A
J Allergy Clin Immunol. 1984 Mar;73(3):369-75. doi: 10.1016/0091-6749(84)90410-x.
A successful program of immunotherapy for Triatoma protracta-induced anaphylaxis was developed. This program included a new passive extract-antigen preparation standardized by RAST inhibition. This antigen facilitated the development of a reliable skin test protocol for in vivo diagnosis of Triatoma protracta allergy. Five patients with T. protracta-induced anaphylaxis underwent a rapidly increasing dosage schedule of immunotherapy. The IgE- and IgG-antibody responses during immunotherapy were followed with solid-phase RIA. Protection against anaphylaxis was confirmed in all patients with a "bite challenge" by T. protracta. This is the first report of completely successful T. protracta immunotherapy.
开发了一种针对长红锥蝽诱发过敏反应的成功免疫治疗方案。该方案包括一种通过放射变应原吸附试验（RAST）抑制作用标准化的新型被动提取物 - 抗原制剂。这种抗原促进了用于长红锥蝽过敏体内诊断的可靠皮肤试验方案的发展。五名患有长红锥蝽诱发过敏反应的患者接受了快速递增剂量的免疫治疗方案。在免疫治疗期间，通过固相放射免疫分析（RIA）跟踪IgE和IgG抗体反应。通过长红锥蝽的“叮咬激发试验”证实了所有患者对过敏反应的防护作用。这是关于长红锥蝽免疫治疗完全成功的首例报告。
